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Background
Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-
receptor–signaling pathway, the major driver of prostate-cancer growth. We aimed 
to evaluate whether enzalutamide prolongs survival in men with castration-resis-
tant prostate cancer after chemotherapy.
Methods
In our phase 3, double-blind, placebo-controlled trial, we stratified 1199 men with 
castration-resistant prostate cancer after chemotherapy according to the Eastern 
Cooperative Oncology Group performance-status score and pain intensity. We ran-
domly assigned them, in a 2:1 ratio, to receive oral enzalutamide at a dose of 160 mg 
per day (800 patients) or placebo (399 patients). The primary end point was overall 
survival.
Results
The study was stopped after a planned interim analysis at the time of 520 deaths. 
The median overall survival was 18.4 months (95% confidence interval [CI], 17.3 to 
not yet reached) in the enzalutamide group versus 13.6 months (95% CI, 11.3 to 
15.8) in the placebo group (hazard ratio for death in the enzalutamide group, 0.63; 
95% CI, 0.53 to 0.75; P<0.001). The superiority of enzalutamide over placebo was 
shown with respect to all secondary end points: the proportion of patients with a 
reduction in the prostate-specific antigen (PSA) level by 50% or more (54% vs. 2%, 
P<0.001), the soft-tissue response rate (29% vs. 4%, P<0.001), the quality-of-life re-
sponse rate (43% vs. 18%, P<0.001), the time to PSA progression (8.3 vs. 3.0 months; 
hazard ratio, 0.25; P<0.001), radiographic progression-free survival (8.3 vs. 2.9 
months; hazard ratio, 0.40; P<0.001), and the time to the first skeletal-related event 
(16.7 vs. 13.3 months; hazard ratio, 0.69; P<0.001). Rates of fatigue, diarrhea, and 
hot flashes were higher in the enzalutamide group. Seizures were reported in five 
patients (0.6%) receiving enzalutamide.
Conclusions
Enzalutamide significantly prolonged the survival of men with metastatic castration-
resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas 
Pharma Global Development; AFFIRM ClinicalTrials.gov number, NCT00974311.)
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Prostate cancer is an androgen-dependent disease that initially responds but later becomes resistant to established 
therapies that reduce circulating testosterone lev-
els or inhibit androgen binding to the androgen 
receptor.1-4 Reactivation of the disease despite cas-
trate levels of testosterone represents a transition 
to the lethal phenotype of castration-resistant 
prostate cancer.5,6 This state was previously called 
androgen-independent or hormone-refractory pros-
tate cancer but is now recognized to be driven by 
androgen-receptor signaling, in part due to over-
expression of the androgen receptor itself.7,8 In 
preclinical models of prostate cancer, androgen-
receptor overexpression shortens the period of tu-
mor latency and confers resistance to conventional 
antiandrogen agents, such as bicalutamide.9
Enzalutamide (formerly MDV3100) is an an-
drogen-receptor–signaling inhibitor chosen for 
clinical development on the basis of activity in 
prostate-cancer models with overexpression of 
the androgen receptor. Enzalutamide is distinct 
from the currently available antiandrogen agents 
in that it inhibits nuclear translocation of the 
androgen receptor, DNA binding, and coactivator 
recruitment. It also has a greater affinity for the 
receptor, induces tumor shrinkage in xenograft 
models (in which conventional agents only retard 
growth), and has no known agonistic effects.10,11
In a phase 1–2 trial enrolling men with castra-
tion-resistant prostate cancer (some of whom had 
undergone previous chemotherapy) conducted by 
the Prostate Cancer Clinical Trials Consortium,12 
enzalutamide had significant antitumor activity 
regardless of previous chemotherapy status. On the 
basis of these findings, a dose of enzalutamide 
was identified for further study.13 In our phase 
3 trial, we evaluated whether enzalutamide would 
prolong life in men with progressive castration-
resistant prostate cancer after chemotherapy. The 
design incorporated the recommendations of the 
Prostate Cancer Clinical Trials Working Group 2 
(PCWG2)14 to avoid premature study-drug discon-
tinuation and to help address previously identified 
difficulties in assessing outcomes in clinical trials 
involving men with prostate cancer.
Me thods
Study Design and Conduct
AFFIRM (A Study Evaluating the Efficacy and 
Safety of the Investigational Drug MDV3100) was 
an international, phase 3, randomized, double-
blind, placebo-controlled study of enzalutamide in 
patients with prostate cancer who had previously 
been treated with one or two chemotherapy regi-
mens, at least one of which contained docetaxel.
The review boards of all participating institu-
tions approved the study, which was conducted 
according to the provisions of the Declaration of 
Helsinki and the Good Clinical Practice Guide-
lines of the International Conference on Harmo-
nization. All patients provided written informed 
consent to participate in the study.
The study was designed and the protocol was 
written by the senior academic authors and rep-
resentatives of one of the sponsors (Medivation). 
The first draft of the manuscript was written by 
the first author, and the manuscript was then com-
pleted and approved by all the authors. All the 
authors were responsible for writing the manu-
script and for the decision to submit the manu-
script for publication, and all the authors assume 
responsibility for the completeness and integrity 
of the data and the fidelity of the study to the pro-
tocol and analysis plan (available with the full 
text of this article at NEJM.org). All the authors 
or authors’ institutions had agreements with the 
sponsor regarding confidentiality of the data. No 
one who is not an author contributed to the writ-
ing of the manuscript.
Study Participants
The study was conducted at 156 sites in 15 coun-
tries. Patients were eligible for enrollment if they 
had a histologically or cytologically confirmed 
diagnosis of prostate cancer, castrate levels of 
testosterone (<50 ng per deciliter [1.7 nmol per 
liter]), previous treatment with docetaxel, and 
progressive disease defined according to PCWG2 
criteria (see the Study End Points section below), 
including three increasing values for prostate-
specific antigen (PSA) or radiographically con-
firmed progression with or without a rise in the 
PSA level.14 A complete list of inclusion and ex-
clusion criteria is provided in the protocol.
Patients were enrolled from September 2009 
through November 2010 and were randomly as-
signed to a study treatment centrally by means of 
an interactive voice-response system after strati-
fication according to the baseline Eastern Coop-
erative Oncology Group (ECOG) performance 
status score (0 or 1 vs. 2) and the Brief Pain In-
ventory–Short Form (BPI-SF) question 3 score ad-
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dressing the average pain over the 7 days before 
randomization (0 to 3 [no pain to mild pain] vs. 
4 to 10 [moderate-to-severe pain]).
ECOG performance scores range from 0 to 5, 
with 0 indicating full activity, 1 indicating a re-
striction in strenuous activity but the ability to 
be ambulatory and do light work, and 2 indicat-
ing an ability to be ambulatory but an inability 
to work.15 Scores on BPI-SF question 3, which asks 
about the worst pain in the previous 24 hours, 
range from 0 to 10, with higher scores reflecting 
a greater severity of pain.16
Patients were randomly assigned in a 2:1 ratio 
to receive enzalutamide (160 mg orally once 
daily as four 40-mg capsules) or matched place-
bo capsules. Permuted-block randomization was 
used. The use of prednisone or other glucocorti-
coids was permitted but not required, and the 
study drug was given without regard to food in-
take. Investigators were encouraged to continue 
study treatment until radiographically confirmed 
disease progression requiring initiation of new 
systemic antineoplastic therapy. The safety and ef-
ficacy data that were collected are described in the 
Supplementary Appendix, available at NEJM.org.
Study End Points
The primary end point was overall survival, 
which was defined as the time from randomiza-
tion to death from any cause. Secondary end points 
included measures of response (in the PSA level, 
in soft tissue, and in the quality-of-life score) and 
measures of progression (time to PSA progression, 
radiographic progression-free survival, and time 
to the first skeletal-related event17).
We used the following definitions of the sec-
ondary end points (as detailed in Table 1S in the 
Supplementary Appendix): PSA-level response was 
defined as a reduction in the PSA level from base-
line by 50% or more or 90% or more, as con-
firmed on an additional PSA evaluation performed 
3 or more weeks later.14 Objective soft-tissue re-
sponse was defined by the Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.1.18 
Quality-of-life response was defined as a 10-point 
improvement in the global score on the Func-
tional Assessment of Cancer Therapy-Prostate 
(FACT-P) questionnaire, as compared with base-
line, on two consecutive measurements obtained 
at least 3 weeks apart.19,20 The FACT-P is a 39-item 
questionnaire on which the score for each item 
can range from 0 to 4, with higher scores indi-
cating a better quality of life.
For the analysis of progression-free survival, 
we used the following measures of progression 
(as indicated by the results of computed tomog-
raphy or magnetic resonance imaging of soft tis-
sue and of radionuclide bone scanning): progres-
sion of soft-tissue disease according to RECIST, 
version 1.118; progression of osseous disease ac-
cording to bone scans showing two or more new 
lesions per PCWG2; and death from any cause. 
Progression in bone at the first scheduled assess-
ment, at week 13, required a confirmatory scan 
performed 6 or more weeks later showing addi-
tional new lesions.14 The times to PSA progression 
and the first skeletal-related event were also re-
corded. PSA progression was defined as an in-
crease by a factor of 1.25 over the baseline level 
(for patients in whom the PSA level had not de-
creased) or over the nadir level (for patients in 
whom the PSA level had decreased) and an in-
crease in the absolute PSA level by at least 2 ng per 
milliliter, which was confirmed by a repeat mea-
surement.14 A skeletal-related event was defined as 
radiation therapy or surgery to bone, pathologic 
bone fracture, spinal cord compression, or change 
of antineoplastic therapy to treat bone pain.17
Statistical Analysis
All analyses were performed by the sponsor us-
ing data obtained as of the cutoff date of Septem-
ber 25, 2011. The primary efficacy end point was 
a between-group comparison of the time from 
randomization to death from any cause (overall 
survival) in the intention-to-treat population (all 
randomly assigned patients). The study was de-
signed to have a power of 90% to detect a hazard 
ratio of 0.76 for death in the enzalutamide group, 
as compared with the placebo group, with a two-
sided type I error rate of 0.05. We planned to 
enroll approximately 1170 patients, assuming a 
median survival of 15.7 months in the enzaluta-
mide group and 12.0 months in the placebo group, 
an accrual period of approximately 12 months, 
and a total study duration of approximately 30 
months to observe the required 650 events.
A single interim analysis was planned to be 
performed after 520 deaths (80% of the 650 total 
events) had occurred. The analysis was done ac-
cording to a group sequential design with the 
use of a Lan–DeMets implementation of the 
O’Brien–Fleming stopping boundary (P<0.02). In 
the primary analysis, we used a log-rank test to 
evaluate overall survival, with stratification ac-
cording to the ECOG performance-status score 
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and the baseline mean pain score (as measured 
by the BPI-SF score); the results are presented as 
Kaplan–Meier curves. Supportive analyses of over-
all survival were performed with the use of the 
unstratified log-rank test and Cox proportional-
hazards models. Subgroup analyses were con-
ducted to determine whether treatment effects 
were consistent across patient subgroups. A mul-
tivariate analysis was also performed.
Only if the overall survival analysis showed 
statistical superiority of enzalutamide over pla-
cebo was the testing of the key secondary end 
points to be undertaken, in the rank-prioritized 
order ― the time to PSA progression, radiograph-
ic progression-free survival, and the time to the 
first skeletal-related event ― with the signifi-
cance of the previous end point gating further 
testing. These end points were tested by means 
of the stratified log-rank test in a protected hier-
archical manner, each at the two-sided signifi-
cance level of 0.05.
R esult s
Patients and Treatment
The study enrolled 1199 patients who were ran-
domly assigned to receive either enzalutamide 
(800 patients) or placebo (399 patients). The en-
rollment, follow-up, and data analysis of patients 
are shown in Figure 1S in the Supplementary Ap-
pendix. Baseline characteristics were well matched 
between groups in terms of demographic charac-
teristics, previous treatment history, and extent of 
disease (Table 2S in the Supplementary Appendix). 
At the time of the interim analysis, the median 
time on treatment was 8.3 months in the enzalu-
tamide group and 3.0 months in the placebo 
group. The median duration of follow-up to ascer-
tain survival status was 14.4 months.
Efficacy
The median overall survival was 18.4 months (95% 
confidence interval [CI], 17.3 to not yet reached) 
among patients receiving enzalutamide and 13.6 
months (95% CI, 11.3 to 15.8) among patients 
receiving placebo (Fig. 1A). At the time of the 
prespecified interim analysis, the use of enzalu-
Figure 1. Kaplan–Meier Estimates of Primary and Sec-
ondary End Points in the Intention-to-Treat Population.
Shown are data for overall survival, the primary end 
point (Panel A), and for two secondary end points, the 
time to prostate-specific antigen (PSA) progression 
(Panel B) and radiographic progression-free survival 
(Panel C), in the enzalutamide group, as compared 
with the placebo group. CI denotes confidence interval.
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tamide resulted in a 37% reduction in the risk of 
death, as compared with placebo (hazard ratio 
for death, 0.63; 95% CI, 0.53 to 0.75; P<0.001). 
On the basis of these results, an independent 
data and safety monitoring committee recom-
mended that the study be halted and unblinded, 
with eligible patients in the placebo group of-
fered treatment with enzalutamide. These results 
were confirmed at the time that the database was 
locked and are presented here.
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Figure 2. Subgroup Analyses of Hazard Ratios for Death in the Two Study Groups.
Hazard ratios are based on a nonstratified proportional-hazards model. Dashes indicate that the median time to death had not been 
reached for the indicated subgroup. The size of the circles is proportional to the size of the subgroup. The horizontal bars represent 
95% confidence intervals. The Eastern Cooperative Oncology Group (ECOG) grades the performance status of patients with respect to 
activities of daily living, with 0 indicating that the patient is fully active and able to carry out all predisease activities without restriction; 
1 indicating that the patient is restricted in physically strenuous activity but is ambulatory and able to carry out work of a light or seden-
tary nature; and 2 indicating that the patient is ambulatory and up and about for more than 50% of waking hours and is capable of self-
care but unable to carry out work activities. Scores on the Brief Pain Inventory–Short Form (BPI-SF) range from 0 to 10, with scores of  
0 to 3 indicating that clinically significant pain is absent and scores of 4 to 10 indicating that clinically significant pain is present, and 
with higher scores indicating greater pain. LDH denotes lactate dehydrogenase, and PSA prostate-specific antigen.
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In the intention-to-treat population, 308 of 
800 patients (39%) died in the enzalutamide 
group and 212 of 399 patients (53%) died in the 
placebo group. When the study was unblinded, 
231 patients (29%) in the enzalutamide group 
were receiving the study drug, as compared with 
only 19 patients (5%) in the placebo group.
The overall survival benefit was consistent 
across all subgroups, including age, baseline 
pain intensity, geographic region, and type of 
disease progression at entry (Fig. 2), and it was 
maintained in the supportive analyses of overall 
survival performed with the use of the unstrati-
fied log-rank test and the Cox proportional-
hazards model. The effect of enzalutamide on 
overall survival was maintained after adjustment 
for stratification factors and baseline prognostic 
factors, as shown in Table 1 in a multivariate 
analysis (hazard ratio for death, 0.58; 95% CI, 
0.49 to 0.70; P<0.001). Systemic antineoplastic 
treatments were used for prostate cancer after 
the study drug was discontinued in a large pro-
portion of patients, more commonly in the pla-
cebo group (in 61% of patients) than in the 
enzalutamide group (in 42% of patients). Among 
patients receiving at least one therapy after dis-
continuation of the study drug, the agents used 
included abiraterone acetate in 21% of patients 
in the enzalutamide group and in 24% of those 
in the placebo group and cabazitaxel in 10% and 
14%, respectively. Both agents have been shown 
to confer a survival benefit for men with this 
disease state (see Table 3S in the Supplementary 
Appendix).
The superiority of enzalutamide over placebo 
was shown for all secondary end points, includ-
ing PSA-level response rate (54% vs. 2%, P<0.001), 
soft-tissue response rate (29% vs. 4%, P<0.001), 
FACT-P quality-of-life response (43% vs. 18%, 
P<0.001), the time to PSA progression (8.3 vs. 3.0 
months; hazard ratio, 0.25; P<0.001) (Fig. 1B), 
radiographic progression-free survival (8.3 vs. 2.9 
months; hazard ratio, 0.40; P<0.001) (Fig. 1C), and 
the time to the first skeletal-related event (16.7 vs. 
13.3 months; hazard ratio, 0.69; P<0.001) (Table 2).
Safety
Though the period of observation for the enzalu-
tamide group was more than twice that for the 
placebo group, the rates of adverse events were 
similar in the two groups (Table 3). The enzalu-
tamide group had a lower incidence of adverse 
events of grade 3 or above (45.3%, vs. 53.1% in 
the placebo group). The median time to the first 
Table 1. Multivariate Analysis of Hazard Ratios for Death.*
Variable Measurement Estimates
Hazard Ratio for 
Death (95% CI)
Coefficient P Value
Study treatment (enzalutamide vs. placebo) −0.54±0.09 <0.001 0.58 (0.49–0.70)
ECOG performance score (0 or 1 vs. 2) −0.33±0.14 0.02 0.72 (0.55–0.95)
Mean pain score on BPI-SF (question no. 3)(<4 vs. ≥4)† −0.23±0.10 0.02 0.79 (0.65–0.97)
Progression at study entry (PSA only vs. radiographic) −0.29±0.09 0.002 0.75 (0.62–0.90)
Visceral disease at screening (no vs. yes) −0.47±0.10 <0.001 0.63 (0.52–0.76)
Baseline serum lactate dehydrogenase (per increase  
of 1 U per liter)
0.00±0.00 <0.001 1.002 (1.001–1.002)
Baseline hemoglobin (per increase of 1 g per liter) −0.03±0.00 <0.001 0.97 (0.97–0.98)
* Data with respect to survival for patients who were alive at the time of analysis were censored at the date the patient 
was last known to be alive. Hazard ratios for death were calculated after adjustment for prognostic factors. Several fac-
tors were entered into a Cox proportional-hazards model, and a stepwise selection method was used in which nonsig-
nificant factors were eliminated at entry into the model (P≥0.10) and further eliminated after the contribution to the 
model was assessed (P≥0.25). These included the factors listed in the table as well as age (<65 years vs.³≥65 years), 
 region (North America vs. other), number of previous chemotherapy regimens (1 vs. 2), and baseline serum prostate-
specific antigen (PSA) level (per increase of 1 ng per milliliter). The Gleason score for prostate tumors was excluded 
owing to a large number of missing values. CI denotes confidence interval, and ECOG Eastern Cooperative Oncology 
Group.
† Scores on the Brief Pain Inventory–Short Form (BPI-SF) range from 0 to 10, with scores of 0 to 3 indicating that clinically 
significant pain is absent and scores of 4 to 10 indicating that clinically significant pain is present, and with higher 
scores indicating greater pain.
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such adverse event was 12.6 months in the enzalu-
tamide group, as compared with 4.2 months in 
the placebo group (Fig. 2S in the Supplementary 
Appendix). There was a higher incidence of all 
grades of fatigue, diarrhea, hot flashes, muscu-
loskeletal pain, and headache in the enzaluta-
mide group than in the placebo group. Cardiac 
disorders were noted in 6% of patients receiving 
enzalutamide and in 8% of patients receiving 
placebo (with cardiac disorders of grade 3 in 1% 
and 2%, respectively). Hypertension or increased 
blood pressure was observed in 6.6% of patients 
in the enzalutamide group and 3.3% of those in 
the placebo group. There were no significant 
between-group imbalances in the rates of other 
adverse events, such as hyperglycemia, weight gain, 
hyperlipidemia, or glucose intolerance. There-
fore, there was no evidence to suggest the devel-
opment of a metabolic syndrome associated with 
enzalutamide, although the study was not de-
signed to formally evaluate this event. Liver-func-
tion abnormalities were reported as adverse events 
in 1% of patients receiving enzalutamide and in 
2% of those receiving placebo.
A comprehensive evaluation of electrocardio-
graphic data, including the QT interval and the 
QT interval corrected for heart rate (QTc), revealed 
no clinically relevant changes in heart rate, atrio-
ventricular conduction, cardiac depolarization, or 
effect on cardiac repolarization as determined 
by means of the QTc according to Fridericia’s 
formula.21
Table 2. Secondary End Points Related to Response and Disease Progression.*
End Point
Enzalutamide 
(N = 800)
Placebo 
(N = 399)
Hazard Ratio 
(95% CI) P Value
Confirmed PSA decline†
Patients with ≥1 postbaseline PSA assessment ―  
no. (%)
731 (91) 330 (83)
PSA response ― no./total no. (%)
Decline ≥50% from baseline 395/731 (54) 5/330 (2) <0.001
Decline ≥90% from baseline 181/731 (25) 3/330 (1) <0.001
Soft-tissue objective response
Patients with measurable disease ― no. (%) 446 (56) 208 (52)
Complete or partial objective response ― no./ 
total no. (%)
129/446 (29) 8/208 (4) <0.001
FACT-P quality-of-life response†
Patients with ≥1 postbaseline assessment ― no. (%) 651 (81) 257 (64)
Quality-of-life response ― no./total no. (%)‡ 281/651 (43) 47/257 (18) <0.001
Progression indicators
Time to PSA progression ― mo 0.25 (0.20–0.30) <0.001
Median 8.3 3.0
95% CI 5.8–8.3 2.9–3.7
Radiographic progression-free survival ― mo 0.40 (0.35–0.47) <0.001
Median 8.3 2.9
95% CI 8.2–9.4 2.8–3.4
Time to first skeletal-related event ― mo 0.69 (0.57–0.84) <0.001
Median 16.7 13.3
95% CI 14.6–19.1 9.9–NYR
* For a complete definition of end points, see Table 1S in the Supplementary Appendix. FACT-P denotes Functional 
Assessment of Cancer Therapy–Prostate, NYR not yet reached, and PSA prostate-specific antigen.
† Only patients with both baseline and postbaseline assessments are included.
‡ The quality-of-life response was defined as a 10-point improvement in the global score on the FACT-P questionnaire, as 
compared with baseline, on two consecutive measurements obtained at least 3 weeks apart.
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Five of the 800 patients in the enzalutamide 
group (0.6%) were reported by the investigators 
to have had a seizure; no seizures were reported 
in the placebo group. One case of status epilep-
ticus (confusion associated with partial complex-
status epilepticus) required medical intervention; 
the four other seizures were self-limited and did 
not recur after study-drug discontinuation. Four 
of the seizures were witnessed. Potentially predis-
posing factors were present in several patients. 
Two patients had brain metastases, 1 of whom 
had a seizure reported 26 days after the last dose 
of enzalutamide. One patient had inadvertently 
been administered lidocaine intravenously im-
mediately before the seizure, and 1 patient with 
brain atrophy had an unwitnessed event classi-
fied as a seizure, in the context of a history of 
heavy alcohol use, after initiation of haloperidol 
7 days beforehand. One additional adverse event 
reported by the investigator as a syncope had 
several features suggestive of seizure.
Discussion
In this phase 3 study, we found that enzaluta-
mide, an oral androgen-receptor–signaling in-
hibitor, significantly prolonged the survival of 
men with metastatic castration-resistant prostate 
cancer after chemotherapy by a median of 4.8 
months and reduced the risk of death from any 
cause by 37% versus placebo. In a multivariate 
analysis, the survival benefit was seen in all pa-
tient subgroups, including those stratified ac-
cording to age and ECOG performance status, 
the geographic location of the study center, the 
extent of disease on diagnostic imaging, and bio-
chemical measurements that included PSA and 
lactate dehydrogenase, even after adjustment for 
baseline factors.
These data confirm the central role of the an-
drogen receptor and androgen-receptor signaling 
in the progression of prostate cancer throughout 
the spectrum of disease. Castration-resistant 
Table 3. Adverse Events, According to Grade.
Adverse Event Enzalutamide (N = 800) Placebo (N = 399)
Any Grade Grade ≥3 Any Grade Grade ≥3
number of patients (percent)
≥1 Adverse event 785 (98) 362 (45) 390 (98) 212 (53)
Any serious adverse event 268 (34) 227 (28) 154 (39) 134 (34)
Discontinuation owing to adverse event 61 (8) 37 (5) 39 (10) 28 (7)
Adverse event leading to death 23 (3) 23 (3) 14 (4) 14 (4)
Frequent adverse events more common with 
enzalutamide*
Fatigue 269 (34) 50 (6) 116 (29) 29 (7)
Diarrhea 171 (21) 9 (1) 70 (18) 1 (<1)
Hot flash 162 (20) 0 41 (10) 0
Musculoskeletal pain 109 (14) 8 (1) 40 (10) 1 (<1)
Headache 93 (12) 6 (<1) 22 (6) 0
Clinically significant adverse events
Cardiac disorder
Any 49 (6) 7 (1) 30 (8) 8 (2)
Myocardial infarction 2 (<1) 2 (<1) 2 (<1) 2 (<1)
Abnormality on liver-function testing† 8 (1) 3 (<1) 6 (2) 3 (<1)
Seizure 5 (<1) 5 (<1) 0 0
* Included in this category are adverse events that occurred in more than 10% of patients in the enzalutamide group and 
that occurred in the enzalutamide group at a rate that was at least 2 percentage points higher than that in the placebo 
group.
† Abnormalities on liver-function testing included hyperbilirubinemia and increased levels of aspartate aminotransferase 
or alanine aminotransferase.
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disease was previously considered to be a hor-
mone-refractory disease. The survival benefit in 
this study substantiates preclinical work show-
ing that androgen-receptor signaling contributes 
to disease progression despite castrate levels of 
testosterone and previous conventional antian-
drogen therapy. This result, coupled with the re-
cent report of a survival benefit from abiraterone 
acetate plus prednisone (probably resulting from 
further reduction in androgen levels),22 estab-
lishes that these tumors are not refractory to 
hormones, even after chemotherapy has been 
administered. Changes in the androgen recep-
tor, including overexpression, not only are onco-
genic in model systems but also are associated 
with growth-stimulatory effects from the avail-
able antiandrogen agents.7-9 Enzalutamide, un-
like bicalutamide and flutamide, has no known 
agonist activity,11 and enzalutamide therapy was 
able to slow disease progression despite the pres-
ence of low levels of circulating androgens.
At the time that this placebo-controlled study 
was designed and initiated, no life-prolonging 
treatment was available for men with progressive 
prostate cancer after docetaxel therapy; however, 
during the study period, both cabazitaxel23 and 
abiraterone acetate plus prednisone21 were ap-
proved for use. The benefits of enzalutamide 
were observed even though a greater proportion 
of patients in the placebo group received subse-
quent systemic therapies for prostate cancer that 
have been shown to prolong life (42% of those 
receiving enzalutamide and 61% of those receiv-
ing placebo). PSA levels increased in a majority 
of patients who had disease progression while 
receiving enzalutamide, a finding that suggests 
the tumors remained driven by androgen and an-
drogen receptors and potentially sensitive to fur-
ther hormonal interventions. 
The analyses of the reported secondary out-
come measures were supportive of the observed 
survival benefit. Enzalutamide was superior to 
placebo both in early measures of response (as 
assessed by improvements in PSA level, radio-
graphically measurable disease, and quality-of-
life scores) and in time-to-event measures of 
progression (as defined by PSA level, diagnostic 
imaging results, and delay in the development of 
skeletal-related events), as outlined in the 
PCWG2 guidelines.14 The significantly higher 
response rates, as well as the prolonged progres-
sion-free survival, with enzalutamide as com-
pared with placebo are consistent with the overall 
clinical benefit of enzalutamide.
The median time to any initial adverse event of 
grade 3 or higher was 8.4 months longer in the 
enzalutamide group than in the placebo group 
(12.6 vs. 4.2 months), owing to improved long-
term control of disease-related symptoms with-
out an increase in drug reactions of grade 3 or 
higher. The most common adverse events that were 
reported more frequently in the enzalutamide 
group included fatigue, diarrhea, and hot flashes. 
Although all men had castrate levels of circulat-
ing testosterone, further inhibition of androgen-
receptor signaling in noncancerous tissues prob-
ably explains some of these side effects.24,25
Seizures were reported in 5 of 800 patients 
(0.6%) receiving enzalutamide, several of whom 
had predisposing conditions or concomitant treat-
ments. Convulsions are a dose-dependent toxic 
effect of enzalutamide given at doses above the 
clinical therapeutic range in animals,26 and sei-
zures were seen in the phase 1–2 enzalutamide 
trial in each of the cohorts, beginning at daily 
doses of 360 mg of enzalutamide or more.13 Inhi-
bition of the γ-aminobutyric acid–gated chloride 
channel is a hypothesized mechanism by which 
enzalutamide lowers the seizure threshold.27 
Caution should be used in administering enzalu-
tamide to patients with a history of seizure or 
who have other predisposing factors, including 
underlying brain injury, stroke, brain metasta-
ses, or alcoholism, or to patients receiving con-
comitant medication that may lower the seizure 
threshold. In this study, enzalutamide was dis-
continued in patients who were reported to have 
had a seizure. Treatment with enzalutamide did 
not result in an increase in the rate of cardiac 
disorders or hepatic dysfunction.
Enzalutamide, a once-daily oral hormonal 
treatment, is administered without the need for 
concomitant prednisone, which has been postu-
lated to activate androgen-receptor signaling.28 
This novel agent is anticipated to join the thera-
peutic armamentarium of anticancer drugs with 
diverse mechanisms of action that confer a sur-
vival benefit in men with castration-resistant pros-
tate cancer.22,23,29 These results validate andro-
gen-receptor signaling as a key therapeutic target 
throughout the clinical spectrum of prostate can-
cer, including in men who have received previous 
chemotherapy. Clinical trials of enzalutamide in 
earlier-stage prostate cancer are ongoing.
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In conclusion, enzalutamide significantly pro-
longed survival in men with metastatic castration-
resistant prostate cancer after chemotherapy.
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